IL17A and COVID-19: Despite multiple evidence suggesting the potential of IL-17 as an intervention target for COVID-CS, studies have shown that the levels of IL-17 were within normal ranges in 102 and 21 patients with mild and severe COVID-19, respectively.147 Therefore, more clinical trials and fundamental research are required for further clarification.